Recce Pharmaceuticals (ASX:RCE) received a notice of allowance from the Japan Patent Office for Patent Family 4 for its anti-infectives, according to a Wednesday filing with the Australian bourse.
The claims relate to RECCE 327 and RECCE 529, which are both designed to treat bacterial and viral infections. The patent will expire in 2041.
Recce Pharmaceuticals' shares were down past 2% in recent trade.